Fig. 3: Hemoglobin level and platelet count changes with treatment. | British Journal of Cancer

Fig. 3: Hemoglobin level and platelet count changes with treatment.

From: Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

Fig. 3

Change in (a) hemoglobin value and (b) platelet count from baseline to the minimum observed postbaseline value. Solid diagonal line represents no change; vertical and horizontal lines are borders between NCI CTCAE grades. Vertical distance from the diagonal represents magnitude of change; above the diagonal is an increase, below a decrease. For analytes in which the reference range varied by age/sex, the lowest value was used to create the borders. Color gradient indicates dose intensity (lighter = lower dose intensity, darker = higher dose intensity). C1 D1 cycle 1, day 1, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, Q3W every 3 weeks.

Back to article page